Tazifylline

CAS No. 79712-55-3

Tazifylline( —— )

Catalog No. M26008 CAS No. 79712-55-3

(±)-Tazifylline is a specific and long-acting antagonist of histamine H1 receptor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 447 Get Quote
10MG 651 Get Quote
25MG 1017 Get Quote
50MG 1368 Get Quote
100MG 1782 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Tazifylline
  • Note
    Research use only, not for human use.
  • Brief Description
    (±)-Tazifylline is a specific and long-acting antagonist of histamine H1 receptor.
  • Description
    (±)-Tazifylline is a specific and long-acting antagonist of histamine H1 receptor.(In Vitro):Tazifylline potently inhibits contractions evoked by stimulation of histamine H1-receptors in isolated guinea pig ilea and exhibits high affinity in radioligand binding studies.(In Vivo):In anesthetized guinea pigs, Tazifylline causes an inhibition in histamine-induced bronchoconstriction and protects conscious animals from the lethal effect of large doses of the amine. In conscious rats, Tazifylline reduces the inflammatory effects of intradermal histamine. In conscious dogs, Tazifylline(orally) causes inhibition in histamine-induced skin inflammation for long periods of time, and in anesthetized animals attenuated that portion of the histamine-evoked hypotension attributable to stimulation of H1 receptors. Large oral doses of Tazifylline do not reduce spontaneous locomotor activity in mice, nor do they produce overt symptoms of behavioral depression in conscious rats.
  • In Vitro
    Tazifylline potently inhibits contractions evoked by stimulation of histamine H1-receptors in isolated guinea pig ilea and exhibits high affinity for these receptors in radioligand binding studies in vitro Tazifylline has much lower affinity for histamine H2-receptors, alpha- and beta-adrenoceptors, 5-hydroxytryptamine and muscarinic receptor subtypes. Tazifylline poorly inhibits the release of histamine from rat peritoneal mast cells.
  • In Vivo
    In rats, guinea pigs and dogs the antihistaminic effect of Tazifylline is rapid in onset and long-lived. In anesthetized guinea pigs, Tazifylline markedly inhibits histamine-induced bronchoconstriction and protects conscious animals from the lethal effect of large doses of the amine. In conscious rats, Tazifylline is more potent in reducing the inflammatory effects of intradermal histamine than that evoked by anaphylactic reaction. In conscious dogs, orally administered Tazifylline inhibits histamine-induced skin inflammation for long periods of time and in anesthetized animals attenuated that portion of the histamine-evoked hypotension attributable to stimulation of H1-receptors. Large oral doses of Tazifylline does not reduce spontaneous locomotor activity in mice, nor do they produce overt symptoms of behavioral depression in conscious rats.
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Histamine Receptor
  • Recptor
    PDE3
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    79712-55-3
  • Formula Weight
    472.61
  • Molecular Formula
    C23H32N6O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cn1c2ncn(CC(O)CN3CCN(CCCSc4ccccc4)CC3)c2c(=O)n(C)c1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Mochizuki N, et al. Cardiovascular effects of NSP-804 and NSP-805, novel cardiotonic agents with vasodilator properties. J Cardiovasc Pharmacol. 1993 Jun;21(6):983-95.
molnova catalog
related products
  • Pitolisant

    A potent and selective antagonist of H3 receptor with Ki/EC50 of 0.16/1.5 nM; no effect on H1, H2, H4 receptors (IC50>10 uM).

  • GSK189254A

    GSK189254A is a potent and specific histamine H3 receptor antagonist (pKi values: 9.59-9.90 and 8.51-9.17 for human and rat H3).

  • Betahistine mesylate

    Betahistine is an antivertigo drug first used for treating vertigo assosicated with Ménière’s disease.